Skip to content

Questionnaire development to capture financial toxicity in cancer patients

Development of a Module to Assess the Patients Financial Burden Related to Cancer Treatment-Financial Toxicity-Phase I - FinTox

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/08/057081
Enrollment
195
Registered
2023-08-30
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D069- Carcinoma in situ of cervix, unspecified Health Condition 2: D019- Carcinoma in situ of digestive organ, unspecified Health Condition 3: D000- Carcinoma in situ of lip, oral cavity and pharynx Health Condition 4: D076- Carcinoma in situ of other and unspecified male genital organs Health Condition 5: D024- Carcinoma in situ of respiratory system, unspecified Health Condition 6: D049- Carcinoma in situ of skin, unspecified Health Condition 7: D099- Carcinoma in situ, uns

Interventions

Intervention1: Nil: The study is an observational study Control Intervention1: Nil: The study is an observational study

Sponsors

University Medical Centre Mainz
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Verified cancer diagnosis (according to ICD-11) - Age 18 years or above - Patients who are literate in English language - Willing to provide written informed consent for participation

Exclusion criteria

Exclusion criteria: Patients who lack the ability to understand and complete the interviews and questionnaires (language proficiency, cognitive functioning as judged by Principal Investigator upon screening inclusion)

Design outcomes

Primary

MeasureTime frame
Number of Issues related to financial toxicity in cancer patientsTimepoint: Day 1

Secondary

MeasureTime frame
Issues related to financial toxicity in cancer patientsTimepoint: Day 1

Countries

Belgium, Chile, Croatia, Cyprus, Egypt, Germany, Greece, India, Israel, Italy, Jordan, Malaysia, Netherlands, Portugal, Turkey, United Kingdom

Contacts

Public ContactDr Manjunath Nookala Krishnamurthy

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

nk.manjunath@gmail.com919920703438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026